Civica Rx To Manufacture & Distribute Insulin At Lower Price Point

Civica Rx plans to manufacture and distribute insulin at a price point that is expected to be significantly lower than current market prices for insulin. The expected consumer cost is set at no more than $30 per vial and no more than $55 for a box of five pen cartridges.

Civica will produce three insulins – glargine, lispro, and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively). Each of which will be available both in vials and prefilled pens.

Civica has entered into co-development and commercial agreement with GeneSys Biologics for the three insulin biosimilars. Civica . . .